P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)

• M. Hamadani,
• M. Coleman,
• R. Boccia,
• J. Duras,
• M. Hutchings,
• P. L. Zinzani,
• R. Cordoba,
• M. B. Oreiro,
• V. Williams,
• M. Stouffs,
• P. Langmuir,
• J.-M. Sancho

Affiliations

M. Hamadani

1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee

M. Coleman

2 Clinical Research Alliance Inc, Westbury

R. Boccia

3 Center for Cancer and Blood Disorders, Bethesda, United States of America

J. Duras

4 Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czechia

M. Hutchings

5 Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark

P. L. Zinzani

6 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy

R. Cordoba

7 Lymphoma Unit, Department of Hematology, Fundación Jimenez Diaz University Hospital

M. B. Oreiro

8 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

V. Williams

9 Incyte Corporation, Wilmington, United States of America

M. Stouffs

9 Incyte Corporation, Wilmington, United States of America

P. Langmuir

9 Incyte Corporation, Wilmington, United States of America

J.-M. Sancho

10 Clinical Hematology Department, Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Barcelona, Spain